COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020

Shana Godfred-Cato, Bobbi Bryant, Jessica Leung, Matthew E Oster, Laura Conklin, Joseph Abrams, Katherine Roguski, Bailey Wallace, Emily Prezzato, Emilia H Koumans, Ellen H Lee, Anita Geevarughese, Maura K Lash, Kathleen H Reilly, Wendy P Pulver, Deepam Thomas, Kenneth A Feder, Katherine K Hsu, Nottasorn Plipat, Gillian Richardson, Heather Reid, Sarah Lim, Ann Schmitz, Timmy Pierce, Susan Hrapcak, Deblina Datta, Sapna Bamrah Morris, Kevin Clarke, Ermias Belay, California MIS-C Response Team, Shana Godfred-Cato, Bobbi Bryant, Jessica Leung, Matthew E Oster, Laura Conklin, Joseph Abrams, Katherine Roguski, Bailey Wallace, Emily Prezzato, Emilia H Koumans, Ellen H Lee, Anita Geevarughese, Maura K Lash, Kathleen H Reilly, Wendy P Pulver, Deepam Thomas, Kenneth A Feder, Katherine K Hsu, Nottasorn Plipat, Gillian Richardson, Heather Reid, Sarah Lim, Ann Schmitz, Timmy Pierce, Susan Hrapcak, Deblina Datta, Sapna Bamrah Morris, Kevin Clarke, Ermias Belay, California MIS-C Response Team

Abstract

In April 2020, during the peak of the coronavirus disease 2019 (COVID-19) pandemic in Europe, a cluster of children with hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome was reported in England* (1). The patients' signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2-4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 (1). The clinical signs and symptoms present in this first cluster included fever, rash, conjunctivitis, peripheral edema, gastrointestinal symptoms, shock, and elevated markers of inflammation and cardiac damage (1). On May 14, 2020, CDC published an online Health Advisory that summarized the manifestations of reported multisystem inflammatory syndrome in children (MIS-C), outlined a case definition,† and asked clinicians to report suspected U.S. cases to local and state health departments. As of July 29, a total of 570 U.S. MIS-C patients who met the case definition had been reported to CDC. A total of 203 (35.6%) of the patients had a clinical course consistent with previously published MIS-C reports, characterized predominantly by shock, cardiac dysfunction, abdominal pain, and markedly elevated inflammatory markers, and almost all had positive SARS-CoV-2 test results. The remaining 367 (64.4%) of MIS-C patients had manifestations that appeared to overlap with acute COVID-19 (2-4), had a less severe clinical course, or had features of Kawasaki disease.§ Median duration of hospitalization was 6 days; 364 patients (63.9%) required care in an intensive care unit (ICU), and 10 patients (1.8%) died. As the COVID-19 pandemic continues to expand in many jurisdictions, clinicians should be aware of the signs and symptoms of MIS-C and report suspected cases to their state or local health departments; analysis of reported cases can enhance understanding of MIS-C and improve characterization of the illness for early detection and treatment.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Geographic distribution of 570 reported cases of multisystem inflammatory syndrome in children — United States, March–July 2020 Abbreviations: DC = District of Columbia; NYC = New York City.

References

    1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607–8. 10.1016/S0140-6736(20)31094-1
    1. Toubiana J, Poirault C, Corsia A, et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic in Paris, France: prospective observational study. BMJ 2020;369:m2094. 10.1136/bmj.m2094
    1. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020. E-pub May 17, 2020.
    1. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771–8. 10.1016/S0140-6736(20)31103-X
    1. Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J Stat Softw 2011;42:1–29. 10.18637/jss.v042.i10
    1. Dufort EM, Koumans EH, Chow EJ, et al.; New York State and CDC Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020;383:347–58. 10.1056/NEJMoa2021756
    1. Whittaker E, Bamford A, Kenny J, et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324:259–69. 10.1001/jama.2020.10369
    1. Feldstein LR, Rose EB, Horwitz SM, et al.; Overcoming COVID-19 investigators and the CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383:334–46. 10.1056/NEJMoa2021680
    1. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T; CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422–6. 10.15585/mmwr.mm6914e4
    1. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65. 10.15585/mmwr.mm6924e2

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe